Owing to the rising patient population, the current asthma and COPD market is growing at a fast pace. Factors such as patent expiry of major drug brands and price erosion will further propel the growth of this market. It has been further analyzed that the global asthma and COPD drug market is expected to grow at a moderate CAGR. Presently, the asthma drug segment commanded the overall asthma and COPD market.
In the medical practice, asthma is defined as a condition in which there is an inflammation and constriction of airways through which a body breathes owing to the various environmental triggers. It has been regarded as a serious medical disorder and it has been estimated that around 300 million people globally are suffering from asthma. The drug therapy is most commonly used for the treatment of asthma and for the prevention of this disorder patients are advised to avoid any type of triggers. Over the past decades, pharmaceutical companies have innovated effective asthma drugs that act faster and efficiently treat asthma. The newest generation of asthma curing drugs such as AstraZeneca's Symbicort, and GlaxoSmithKline's Advair are estimated to command a major gain over the older products available in the market.
However, AstraZeneca, GlaxoSmithKline, and Merck are expected to be the market leaders until their drug patents expire in the future years. Drugs such as Singulair, Symbicort, and Advair are estimated to command the highest share in the asthma and COPD market during the forecast period. Presently, Advair was observed to be the market leader to treat asthma followed by Singulair which was the second largest revenue generating drug in terms of revenue.
Also, owing to the high demand of new drug entrants in combinational therapies, inhaled corticosteroids and beta-agonists, there is an intense competition in the asthma market. There are numerous growing opportunities in the asthma and COPD market as majority of large companies are concentrating on contract manufacturing outsourcing (CMO). Also, the key market players are engaged in the development of new products that provide better treatment for asthma.
This research report is designed to analyze and estimate the performance, market demand, and size of the global asthma and COPD market across the world. This report includes historical data and forecasts and market size, value chain, product sales, their forecasts, pipeline products and various other key factors that are boosting or impeding the growth of this market. The major factors driving this market is rising awareness about the diagnosis for Asthma and COPD, and availability of affordable healthcare equipment for the determination of illness in the rural areas. These factors are set to propel the growth of this market and provide immense growth opportunities for companies across the globe. There has been a significant rise in the number of patients suffering with asthma in China over the current years. Factors such as rapid urbanization, air pollution, rising smoking activities, and lifestyle change are bolstering this growth. In the urban China towns, there is a higher occurrence of asthma symptoms as compared to the rural areas.
Owing to the high demand of new drug entrants in combinational therapies, inhaled corticosteroids and beta-agonists, there is an intense competition in the asthma market. Also, the key market players are engaged in the development of new products that provide better treatment for asthma. The players in the asthma and COPD drug market are Novartis AG, GlaxoSmithKline (GSK), Merck & Co., Boehringer Ingelheim, Abbott Laboratories, AstraZeneca, Teva Pharmaceutical Industries, Roche Holding AG, Vectura Group, and Pfizer. Other players in the value chain include Aerovance Inc., Mylan, Alkermes Inc., Genentech Inc., Almirall SA, Sepracor, Inc., and Skyepharma plc.